Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025. Record net sales of 2.448 billion USD, representing net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix Double-digit growth in both International markets and the U.S., with strong performance across all product categories, including year-on-year growth of 9.8% for Injectable Aesthetics, 7.7% for Der...

Forrester (Nasdaq: FORR) today announced the full conference agenda for its B2B Summit EMEA 2025, which will take place in London and digitally on 6–8 October 2025. B2B leaders are facing a pivotal moment amidst shifting buyer demands, rising AI influence, economic uncertainty, and evolving global regulations. At B2B Summit EMEA, leaders will learn how to adapt their marketing, sales, and customer success strategies to address these dynamic changes. The event will focus on aligning cross-func...

Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to...